Loading stock data…
NAUT
$2.70+0.07 (+2.66%)
Market ClosedLast close May 1
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Nautilus Biotechnology, Inc. in the Healthcare sector is trading at $2.70. The stock is currently 37% below its 52-week high of $4.31, remaining 50.8% above its 200-day moving average. Technical signals show neutral RSI of 41 and bearish MACD signal, explaining why NAUT maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 41) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.70
Potential Upside
5%
Whystock Fair Value$2.84
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, whic...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$363.24M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.99
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-41.85%
Volume
Today's trading volume
263,789
Recent News
Nautilus Biotechnology Inc (NAUT) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...
Nautilus Biotechnology Inc (NAUT) reports decreased operating expenses and strategic progress towards commercialization, despite revenue recognition challenges.
Nautilus Biotechnology Q1 Earnings Call Highlights
Nautilus Biotechnology (NASDAQ:NAUT) reported first-quarter 2026 results and highlighted progress toward its planned commercialization timeline, with management emphasizing expanding early customer engagement, advancing its assay portfolio, and maintaining what it described as a cash runway through
Here is Why Nautilus Biotechnology (NAUT) is One of the Best Life Sciences Penny Stocks to Buy
Nautilus Biotechnology Inc. (NASDAQ:NAUT) is one of the 8 Best Life Sciences Penny Stocks to Buy. On March 18, Nautilus Biotechnology Inc. (NASDAQ:NAUT) announced Baylor College of Medicine as the first customer of Nautilus’s Iterative Mapping Early Access Program. Baylor will be utilizing the Nautilus single-molecule proteomics technology through a National Institutes of Health U01 […]
Nautilus Biotechnology Unveils Voyager Proteomics Platform, Targets Beta Access in 2H and Launch Next Year
Nautilus Biotechnology (NASDAQ:NAUT) executives outlined the company’s strategy to “unlock the power of the proteome” and argued that better protein measurement tools could improve drug development, diagnostics, and the use of artificial intelligence in biology. Founder and CEO Sujal Patel, joined
Nautilus Biotechnology And 2 Other Compelling Penny Stocks For Your Watchlist
Over the last 7 days, the U.S. market has dropped by 2.3%, though it has shown a robust increase of 13% over the past year, with earnings projected to grow by 16% annually in the coming years. In such fluctuating conditions, identifying stocks with strong fundamentals and solid balance sheets can be crucial for investors seeking growth opportunities at lower price points. Penny stocks, often representing smaller or newer companies, continue to present underappreciated potential for growth and...